Skip to main content

Table 1 Quantitative dose reduction steps according to baseline molecular status

From: Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trial

Baseline molecular status

Maximum dose reduction 1 (compared to patient’s starting dose)

Maximum dose reduction 2 (compared to reduced dose)

MR3-MR4 (BCR-ABL1 levels ≤ 0.1% and 0.01% on the International Scale (IS), respectively)

25%

25%

MR4.5-MR5 (BCR-ABL1 levels ≤ 0.0032% and 0.001% on the IS, respectively)

25%

50%